Bladder Cancer
Diagnosis and Clinical Management
- English
- ePUB (mobile friendly)
- Available on iOS & Android
About This Book
B ladder Cancer: Diagnosis and Clinical Management is a 100% clinically-focused guide to bladder cancer, providing practical, modern and evidence-based guidance to the latest in diagnosis and management of the condition. It differs from other books in its complete clinical focus as opposed to a heavy analysis of pathogenesis or basic science. As a result, practicing urologists and oncologists in the clinical setting will find it an essential resource to consult.
In addition to the latest in diagnostic tools and imaging methods, core focus is on the management of each form of cancer at its various stages with up to date genomic data and targeted therapies. Both drug therapies and the range of surgical options are covered, ensuring that this is the perfect tool for clinicians to consult when considering which type of management program is appropriate for each individual patient. A key addition is the final section dedicated to optimizing health care delivery, featuring chapters on highly topical issues such as quality of life, patient advocacy and surgical education.
Full color throughout, and packed with excellent images, each chapter contains concise and didactic practical tips and tricks to enrich the reading experience, in addition to management algorithms and the very latest guidelines from the ASCO, AUA, ESMO and EAU concerning clinical management of bladder cancer.
Frequently asked questions
Information
PART I
Diagnosis and treatment of non-muscle-invasive bladder cancer
CHAPTER 1
Pathology
KEY POINTS
- Bladder cancer is a heterogeneous disease that encompasses superficial lesions of papillary or flat phenotype as well as invasive disease.
- Superficial bladder cancer may include lesions with different morphology and biology such as low-grade and high-grade papillary urothelial carcinoma, flat urothelial carcinoma (in situ) and invasive urothelial carcinoma into the lamina propria.
- Multiple grading systems for bladder cancer exist but the most commonly used grading scheme is adopted by the World Health Organization (WHO/International Society of Urological Pathology (ISUP)) and divides papillary carcinomas into low-grade and high-grade instead of the three-tier system of Grades 1, 2, and 3; the Who system also introduced a papillary lesion with very low risk of progression in PUNLMP (papillary urothelial neoplasm of low malignant potential).
- Divergent differentiation is a common phenomenon in bladder cancer, most commonly present in the forms of squamous and glandular phenotypes.
- The vast majority of bladder cancer is of the urothelial type but many subtypes or variants also exist within the spectrum of urothelial neoplasia, some of which may be clinically relevant.
Benign urothelium
Reactive urothelium
Urothelial hyperplasia
Table of contents
- Cover
- Title page
- Table of Contents
- List of contributors
- Preface
- Acknowledgments
- PART I: Diagnosis and treatment of non-muscle-invasive bladder cancer
- PART II: T2-4
- PART III: Primary bladder-sparing therapy
- PART IV: Urinary tract reconstruction
- PART V: Treatment of regionally advanced and metastatic bladder cancer
- PART VI: Genomics and the current status of urothelial cancer
- PART VII: Optimizing healthcare delivery
- Index
- End User License Agreement